Erste Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Erste Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.37M	Hold	133,700	–	–	0.03%	328
2026 Q1	$2.82M	Hold	133,700	–	–	0.03%	325
2025 Q4	$3.64M	Hold	133,700	–	–	0.03%	300
2025 Q3	$2.85M	Sell	133,700 -46,600	-26%	-$1.1M	0.03%	314
2025 Q2	$3.99M	Sell	180,300 -62,000	-26%	-$1.15M	0.03%	304
2025 Q1	$4.14M	Hold	242,300	–	–	0.05%	240
2024 Q4	$4.11M	Hold	242,300	–	–	0.05%	254
2024 Q3	$3.8M	Hold	242,300	–	–	0.05%	265
2024 Q2	$3.97M	Hold	242,300	–	–	0.05%	250
2024 Q1	$4.41M	Buy	242,300 +94,000	+63%	+$2.33M	0.06%	240
2023 Q4	$4.65M	Buy	148,300 +15,700	+12%	+$375K	0.07%	232
2023 Q3	$2.85M	Buy	132,600 +42,000	+46%	+$1.14M	0.05%	246
2023 Q2	$2.17M	Hold	90,600	–	–	0.04%	279
2023 Q1	$1.69M	Hold	90,600	–	–	0.03%	297
2022 Q4	$1.45M	Hold	90,600	–	–	0.03%	306
2022 Q3	$1.46M	Hold	90,600	–	–	0.03%	313
2022 Q2	$1.29M	Hold	90,600	–	–	0.03%	325
2022 Q1	$2.21M	Sell	90,600 -10,900	-11%	-$264K	0.04%	282
2021 Q4	$2.43M	Hold	101,500	–	–	0.04%	279
2021 Q3	$1.72M	Hold	101,500	–	–	0.03%	288
2021 Q2	$2.45M	Hold	101,500	–	–	0.05%	266
2021 Q1	$2.61M	Hold	101,500	–	–	0.06%	239
2020 Q4	$5.46M	Sell	101,500 -21,000	-17%	-$1.04M	0.15%	167
2020 Q3	$4.95M	Buy	122,500 +18,500	+18%	+$799K	0.17%	146
2020 Q2	$5.01M	Sell	104,000 -11,000	-10%	-$528K	0.2%	132
2020 Q1	$4.75M	Buy	115,000 +57,800	+101%	+$2.38M	0.28%	108
2019 Q4	$2.52M	Buy	57,200 +11,000	+24%	+$479K	0.11%	179
2019 Q3	$1.7M	Hold	46,200	–	–	0.09%	203
2019 Q2	$1.22M	Hold	46,200	–	–	0.06%	230
2019 Q1	$1.23M	Hold	46,200	–	–	0.07%	227
2018 Q4	$714K	Buy	+46,200	New	+$897K	0.05%	268

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Erste Asset Management's ACAD Position: Q2 2026 in Review

Erste Asset Management held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 133,700 shares worth $3.37M. The position accounts for 0.03% of the portfolio, ranked #328.

Erste Asset Management first reported a position in ACAD in Q4 2018 and has held it in 31 quarters since. The position peaked at $5.46M in Q4 2020. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Erste Asset Management held 133,700 shares of Acadia Pharmaceuticals worth $3.37M as of Q2 2026.
Erste Asset Management left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up 0.03% of Erste Asset Management's portfolio in Q2 2026, its #328 holding.
Erste Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
Erste Asset Management's Acadia Pharmaceuticals position peaked at $5.46M in Q4 2020.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.